

Agenda

Session 1: HCC Pathogenesis

Moderator: Dongyin Guan (UPenn/BCM)

8:00 – 8:15	Hashem El-Serag	Introduction: HCC in Texas and Role of TeCH	Baylor College of Medicine
8:20 – 8:50	Lewis Roberts	Pathogenesis of HCC: Current status and Future Directions	Mayo Clinic
8:50 – 9:00	Discussion		
9:00 – 9:20	Shuang Liang	Role of CMPK2 in HCC	UT Southwestern
9:20 – 9:40	Robert Tsai	Nuclesteomin in HCC	Texas A&M
9:40 – 10:00	Randy Johnson	Hippo Pathway genetic screen for regulators of Yap/Taz driven HCC	MD Anderson Cancer Center
10:00 – 10:30	Discussion		
10:30 – 11:00	Break		

Session 2: Case Studies

Moderators: Amit Singal (UTSW) / Tannaz Armaghany (BCM)

11:00 – 11:45	Keynote Speaker (Josep Llovet)	Current status of HCC Treatment Landscape and Clinical Trial design for Novel Therapies	Mount Sinai
11:45 – 12:00	Discussion		
12:00 – 1:00	Nicole Rich and George Cholankeril	Case Studies / Lunch Break	UT Southwestern / Baylor College of Medicine

Session 3: HCC Treatment

Moderator: Hashem El-Serag (BCM)

1:00 – 1:20	David Hsieh	Splicing modulators in HCC as immunotherapy adjuvants	UT Southwestern
1:20 – 1:40	David Tweardy	TTI-101 (formerly C188-9), an oral STAT3 inhibitor, for HCC treatment and prevention	MD Anderson Cancer Center
1:40 – 2:00	David Steffin	IL-15 and 21-armored glypican-3 CAR T Cells for HCC	Baylor College of Medicine
2:00 – 2:20	Dan Siegwart	MicroRNA and CRISPR for HCC	UT Southwestern
2:20 – 2:40	Bingning Dong	Targeting fatty acid synthesis in NAFLD-related HCC	Baylor College of Medicine
2:30 – 3:00	Discussion / Wrap-Up		